Showing results (221-230 of 239) with videos related to
Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung CancerJiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.The New England Journal of Medicine|April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaPaul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)T R Cottrell, E D Thompson, P M Forde, et al.Journal for Immunotherapy of Cancer|January 8, 2025
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharingJanis M Taube, Joel C Sunshine, Michael Angelo, et al.The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.The New England Journal of Medicine|November 3, 2016
Fulminant Myocarditis with Combination Immune Checkpoint BlockadeDouglas B Johnson, Justin M Balko, Margaret L Compton, et al.Cancer Immunology Research|April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCPaul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.Science (New York, N.Y.)|June 11, 2021
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockadeSneha Berry, Nicolas A Giraldo, Benjamin F Green, et al.The New England Journal of Medicine|June 2, 2015
PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyDung T Le, Jennifer N Uram, Hao Wang, et al.Nature Immunology|October 25, 2024
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinomaDaniel H Shu, Won Jin Ho, Luciane T Kagohara, et al.Pageof 24